Bengaluru-based firm Eyestem secured $6.4 million in Series A funding round, taking its valuation to $46.4 million. The round was led by three pharmaceutical companies Biological E, Alkem Laboratories and Natco and saw the participation of existing investors Endiya Partners and Kotak Private Equity. "We'll remain focused on solidifying our cell therapy platform," Eyestem CEO said.